Regeneron Pharma (REGN) Survey Confirms Eylea Remains King - Piper Sandler

Piper Sandler analyst Christopher Raymond reiterated an Overweight rating and $692.00 price target on Regeneron Pharma (NASDAQ: REGN) after surveying Ophthalmologists on the use of branded and biosimilar VEGF therapies for AMD, DR, and DME.

The analyst stated "Eylea is king, and expected to remain as such at least in the near term. In this, the first of a series of ophthalmologist surveys (n=75, fielded Nov/Dec) by our partners at Spherix Global Insights, we take a hard look at current market share dynamics and early perceptions of approved and yet-to-be-approved biosimilar VEGF options. Notably, we highlight that for the time being, Eylea remains the dominant option – branded or unbranded with 42% patient share across a user base of 96%. A somewhat distant second is Avastin with 36% share across 87% of docs. Notably, when asked to project share out 6 months, docs project the largest increase for Eylea, over any other option – branded or biosimilar."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $608.98 yesterday.

You May Also Be Interested In

• Monopar Therapeutics (MNPR) PT Raised to $133 at BTIG
• BofA Securities Downgrades LENZ Therapeutics Inc (LENZ) to Neutral
• ARAMARK Holdings (ARMK) PT Raised to $70 at Jefferies